LCM MRD™ (capillary VDJ clonality ID)

Highlights:

  • Capillary PBMCs (cPBMCs) were isolated and characterized via TimepointDx LCM™ for multiple immunotypes via integrated immune repertoire analysis.
  • Clonal identification and subsequent tracking of dominant immunotypes (all dominant clones) prior to treatment (baseline) were tracked on a weekly, bi-weekly, and monthly cadence to identify disease progression and remission faster than traditional methods.
  • TimepointDx LCM™ screened the totality of all cPBMCs from each timepoint collection, ranging from 500,000 to 2,000,000 cPBMCs per collection.
  • TimepointDx LCM™ is inclusive of all variable-diversity-joining (VDJ) regions in addition to translocation regions such as Ig and BCL, which are commonly assessed in leukemias (particularly CLL).
  • The dominant clonotype is continuously tracked within capillary blood collections, particularly where high tumor burden exists, subsequently followed by therapy to quantify overall burden of the clonotype over time.
  • TimepointDx LCM™ tracks the B-cell immune repertoire at baseline, whereby the quantification frequency for the level of residual disease is based on the number of dominant sequences that are identified within the capillary PBMC cell population over time. 
  • TimepointDx LCM™ enables a minimum interval of 1 week (52 timepoints per year) to monthly (12 timepoint per year) of MRD tracking by clonality over multiple years as desired.

See White Paper for Details.

Want the white paper? Contact us below!